EGFR and non-small cell lung carcinoma: In previous work, we showed a synthetic lethal combination of PLK1 inhibition and TRAIL in EGFR-mutant NSCLC cell lines [13]; however, the impact of PLK1 targeting on the EGFR signaling pathway remained unexplored.